Abstract: [Problem] To provide a compound useful as a novel agent which is excellent in preventing and/or treating cannabinoid receptor type 2-related diseases, based on agonist action on a cannabinoid receptor type 2 [Means for Solution] The present inventors conducted thorough investigation regarding compounds having agonist action on a cannabinoid receptor type 2. They confirmed that the fused ring pyridine compound of the present invention has excellent agonist action on the cannabinoid receptor type 2, thereby completing the present invention. The fused ring pyridine compound of the present invention has agonist action on the cannabinoid receptor type 2, and can be used as an agent for preventing and/or treating cannabinoid receptor type 2-related diseases, for example, inflammatory diseases and pain.

Abstract: The present invention relates to a novel compound or a salt thereof, which is useful as a CRTH2 antagonist, especially as a medicament for disorder that participates eosinophil, for example, allergic disorder such as asthma, allergic rhinitis, allergic dermatitis, conjunctival inflammation, hives, eosinophilic bronchitis, food allergy, inflammation of the nasal sinuses, multiple sclerosis, angiitis, or chronic obstructive pulmonary disease (COPD) and the like.

Abstract: To provide a compound which has an excellent activity to modulate the functions of CCR4 or TARC and/or MDC and can be used for the prevention and/or treatment of various inflammatory diseases, allergic diseases, autoimmune diseases and the like. An acylaminopiperidine compound represented by the formula (I) or a pharmaceutically acceptable salt thereof. [Symbols in the formula represent the following meanings; A: a single bond or C1-C6 alkylene, R1: phenyl which may be substituted, etc., R2: —H or C1-C6 alkyl, R3: —H, C1-C6 alkyl or C3-C8 cycloalkyl, R4: pyrrolidin-2-yl which may be substituted, etc., and D: benzene ring or pyrazole ring].

Abstract: The present invention relates to a novel compound or a salt thereof, which is useful as a CRTH2 antagonist, especially as a medicament for disorder that participates eosinophil, for example, allergic disorder such as asthma, allergic rhinitis, allergic dermatitis, conjunctival inflammation, hives, eosinophilic bronchitis, food allergy, inflammation of the nasal sinuses, multiple sclerosis, angiitis, or chronic obstructive pulmonary disease (COPD) and the like.

Abstract: [Problem] To provide a compound which has an excellent activity to modulate the functions of CCR4 or TARC and/or MDC and can be used for the prevention and/or treatment of various inflammatory diseases, allergic diseases, autoimmune diseases and the like. [Means for Resolution] An acylaminopiperidine compound represented by the formula (I) or a pharmaceutically acceptable salt thereof. [Symbols in the formula represent the following meanings; A: a single bond or C1-C6 alkylene, R1: phenyl which may be substituted, etc., R2: —H or C1-C6 alkyl, R3: —H, C1-C6 alkyl or C3-C8 cycloalkyl, R4: pyrrolidin-2-yl which may be substituted, etc., and D: benzene ring or pyrazole ring].

Abstract: Imidazole compounds having adenosine deaminase inhibitory activity represented by the formula (I): wherein R1 is optionally substituted aryl or optionally substituted heteroaryl, R2 is lower alkyl; R3 is hydroxy or protected hydroxy; X is O or S; and -A- is lower alkylene, its prodrug, or their salt.

Abstract: A compound of the formula (1): wherein R1 is cyano, and the like; R2 is hydroxy, and the like; R3 is (lower)alkoxy, and the like; X and Y are each CH or N; or pharmaceutically acceptable salts thereof, which are useful as a medicament.

Abstract: Imidazole compounds having adenosine deaminase inhibitory activity represented by the formula (I) wherein R1 is aryl or heterocyclic group which is optionally substituted with substituent(s); R2 is lower alkyl; R3 is hydroxy or protected hydroxy; -A- is lower alkylene; and —X— is —O— or —S—; provided that when then R1 is aryl which is substituted with substituent(s), or heterocyclic group which is optionally substituted with substituent(s), its prodrug, or their salt. The compounds are useful for treating and/or preventing diseases for which adenosine is effective.

Abstract: This invention relates to piperazine derivatives of the formula: wherein each symbol is as defined in the description, and its pharmaceutically acceptable salt, to processes for preparation thereof, to pharmaceutical composition comprising the same, and to a use of the same for treating or preventing Tachykinin-mediated diseases in human being or animals.

Abstract: Imidazole compounds having adenosine deaminase inhibitory activity represented by the formula (I): wherein R1 is optionally substituted aryl or optionally substituted heteroaryl, R2 is lower alkyl; R3 is hydroxy or protected hydroxy; X is O or S; and -A- is lower alkylene, its prodrug, or their salt. The compounds are useful for treating and/or preventing diseases for which adenosine is effective.

Abstract: Imidazole compounds having adenosine deaminase inhibitory activity represented by the formula (I) wherein R1 is aryloxy, or aryl which is optionally substituted with suitable substituent(s); R2 is lower alkyl; R3 is hydroxy or protected hydroxy; and -A- is lower alkylene, its prodrug, or their salt. The compounds are useful for treating and/or preventing diseases for which adenosine is effective.

Abstract: This invention relates to piperazine derivatives of the formula: wherein each symbol is as defined in the description, and its pharmaceutically acceptable salt, to processes for preparation thereof, to pharmaceutical composition comprising the same, and to a use of the same for treating or preventing Tachykinin-mediated diseases in human being or animals.

Abstract: Imidazole compounds having adenosine deaminase inhibitory activity represented by the formula (I) wherein R1 is aryl or heterocyclic group which is optionally substituted with substituent(s); R2 is lower alkyl; R3 is hydroxy or protected hydroxy; -A- is lower alkylene; and —X—is —O— or —S—; provided that when then R1 is aryl which is substituted with substituent(s), or heterocyclic group which is optionally substituted with substituent(s), its prodrug, or their salt. The compounds are useful for treating and/or preventing diseases for which adenosine is effective.

Abstract: Imidazole compounds having adenosine deaminase inhibitory activity represented by the formula (I) wherein R1 is aryloxy, or aryl which is optionally substituted with suitable substituent(s); R2 is lower alkyl; R3 is hydroxy or protected hydroxy; and -A- is lower alkylene, its prodrug, or their salt. The compounds are useful for treating and/or preventing diseases for which adenosine is effective.

Abstract: Heterocyclic compounds of the following formula: wherein B is  [wherein R1 is hydrogen or lower alkyl; R2 is hydrogen or lower alkyl; and X is hydrogen or hydroxy protective group], lower alkanoyl or hydroxyimino(lower)alkyl A is lower alkylene; W is heterocyclic or carbocyclic group, each of which may have one or more substituent(s); Z is heterocyclic group selected from the group consisting of imidazolyl, triazolyl,imidazopyridyl and adenyl, each of which may have one or more substituent(s); or a salt thereof, provided that when W is aryl which may have one or more substituent(s), then (i) Z is triazolyl, imidazopyridyl or adenyl, each of which may have one or more substituent(s); (ii) Z is imidazolyl which may have one or more substituent(s) and B is lower alkanoyl or hydroxyimino(lower)alkyl; or (iii) Z is imidazolyl which may have one or more substituent(s) and R1 and R2 are both lower alkyl.

Abstract: This invention relates to piperazine derivatives of formula (I), wherein Y is bond or lower alkylene, R1 is aryl which may have substituent(s), R2 is aryl or indolyl, each of which may have substituent(s), R3 is hydrogen or lower alkyl, and R4 is as defined in the description, and its pharmaceutically acceptable salt, to processes for preparation thereof, to pharmaceutical composition comprising the same, and to a use of the same for treating or preventing Tachykinin-mediated diseases in human beings or animals.

Abstract: Imidazole compounds having adenosine deaminase inhibitory activity represented by formula (I) wherein R1 is hydrogen, hydroxy, protected hydroxy, or aryl optionally substituted with suitable substituent(s); R2 is hydrogen or lower alkyl; R3 is hydroxy or protected hydroxy; R4 is cyano, (hydroxy)iminoamino(lower)alkyl, carboxy, protected carboxy, heterocyclic group optionally substituted with amino, or carbamoyl optionally substituted with suitable substituent(s); and —A— is —Q— or —O—Q—, wherein Q is single bond or lower alkylene, provided that when R2 is lower alkyl, then R1 is hydroxy, protected hydroxy, or aryl optionally substituted with suitable substituent(s), its prodrug, or their salt. The compounds are useful for treating and/or preventing diseases for which adenosine is effective.

Abstract: This invention relates to piperazine derivatives of the formula: 1

Abstract: A compound of the formula (I): wherein: R1 is chlorine, difluoromethyl, trifluoromethyl or cyano; and R2is a group having the formula:  wherein: X is halogen, cyano, nitro or amino; Y1 is lower alkyl or lower alkoxy; and Z is halogen; or a pharmaceutically acceptable salt thereof.

Abstract: This application is a 371 of PCT/JP96/03641 filed Dec. 12, 1996.